Business
Football player Jordan Poyer found healing with ayahuasca and is bringing his awareness of psychedelic medicines and breathwork to his Breath of Life tour.
AI, alternative wellness, and gray market products galore dominate the discourse at the PsyCon Denver conference.
Industry insiders weigh in on the growing pains of Oregon’s regulated psilocybin program which has seen concerns raised about licensing fees and some service centers close.
The FDA acceptance of Compass Pathway’s Investigational New Drug Application for their COMP360 compound as a possible therapy for PTSD introduces a new area of possible therapies using psilocybin.
After a challenging year in the wake of the FDA decision on MDMA-assisted therapy for PTSD, the MAPS Board of Directors has embraced a new model of leadership, naming Betty Aldworth and Ismail Lourido Ali as co-executive directors.
The future of ibogaine therapy was a central topic at the 2025 Psychedelic Science conference, where it was endorsed by former Texas governor Rick Perry and others. Other states are following suit, but some advocates worry about possible exploitation of the plant medicine.
Although the safety status of regulated psilocybin services in Oregon has not raised alarm bells since their rollout, providers remain frustrated by the high cost of the services and the difficulty in marketing them to people who could benefit.
Has the psilocybin therapy industry peaked already in Oregon? Growth is slow, and uncertainty reigns, but safeguards seem to be working.
Entrepreneurs Nick Janicki of the float tank company True REST and Robin Arnott of the “digital psychedelic” company SoundSelf are teaming up to create centers that they say will offer clinical ketamine treatment together with prep and integration services including float tanks, music, and light technologies.
The second annual Psychedelics as Medicine Conference will gather influential researchers and policy makers in Reykjavik, Iceland for a two-day conference.
